We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Exploring the Link Between the Triglyceride-Glucose Index and Hypertension Incidence in Japanese Adults

MedXY Editorial Team•Oct 2, 2025•Cardiology
cardiovascular riskHypertensionJapanese PopulationTriglyceride-Glucose Index

Study Background and Disease Burden

Hypertension remains a significant public health challenge, contributing to increased morbidity and mortality worldwide. In Japan, the prevalence of hypertension among adults is notably high, with estimates suggesting that approximately 43% of the adult population lives with high blood pressure. The rising incidence of hypertension is closely linked to lifestyle factors, including diet, physical inactivity, and metabolic disorders such as obesity and diabetes. Given the established role of metabolic disorders in the pathogenesis of hypertension, identifying reliable biomarkers that can predict hypertension risk is crucial for public health interventions and clinical management.

The triglyceride-glucose (TyG) index, a simple composite marker derived from triglyceride and glucose levels, has gained attention in recent years. Studies have suggested that it may serve as a surrogate marker for insulin resistance and cardiovascular risk. This investigation aimed to clarify the relationship between the TyG index and the incidence of hypertension among the Japanese population through a population-based observational study.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Genetically Mediated LDL Cholesterol Variations and Their Limited Impact on Venous Thromboembolism RiskThis study reveals that lifelong genetic differences in LDL cholesterol levels do not significantly affect the risk of venous thromboembolism (VTE), suggesting LDL-C may not be a major causal factor in VTE development.Sep 25, 2026Enhancing Prognosis in Stable Coronary Artery Disease: Insights from a Nationwide Cohort on FFR-CTThis large nationwide study demonstrates that coronary CTA-derived FFR-CT strongly predicts future myocardial infarction, cardiovascular death, and revascularization, independent of traditional risk factors and stenosis severity, with a thrSep 25, 2026Unexpected Early Postoperative Lipid Deterioration in Cushing’s Syndrome: Implications for Cardiovascular Risk and ManagementThis study reveals that lipid profiles paradoxically worsen during the early remission phase after curative surgery for Cushing’s syndrome, highlighting a critical window for cardiovascular risk and targeted intervention.Sep 22, 2026Unveiling the Role of Angiotensin II-Driven TGF-β1 in Enhancing Platelet PAR4 Expression and Thrombotic Risk in Hypertension
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
This study reveals that angiotensin II via TGF-β1 upregulates platelet PAR4, promoting hyperactivation and thrombosis in hypertension, with valsartan attenuating this pathway and thrombotic risk.
Sep 21, 2026
Efficacy and Safety of Low-Dose Rivaroxaban in Advanced Chronic Kidney Disease with High Cardiovascular Risk: A Comprehensive ReviewLow-dose rivaroxaban failed to reduce cardiovascular events but increased major bleeding in advanced CKD patients at high cardiovascular risk, underscoring the need for cautious anticoagulant use.Sep 21, 2026
A Synopsis of the 2025 VA/DoD Lipid Management Guideline: What Clinicians Need to KnowConcise review of the 2025 VA/DoD lipid guideline: new risk tool (PREVENT), CAC and one-time Lp(a) for risk refinement, statins for selected primary prevention groups (including people with HIV), and intensified combination therapy for verySep 19, 2026